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Background: Isolation of mycobacteria in cystic fibrosis (CF) patients is increasingly being reported. Because of
having long term antimicrobial treatment, CF patients are at risk of pulmonary infection with especially resistant
nontuberculous mycobacteria (NTM) strains. The aim of the present study is to determine the prevalence of
mycobacterium spp. and antimicrobial susceptibility in Turkish CF patients.
Methods: During a 5.5 year study period, 376 sputa from 130 CF patients were analyzed. Antimycobacterial
susceptibility testing was performed by the Bactec 460 TB System and the E test method.
Results: Totaly 28 (7.44%) Mycobacterium spp. were isolated from eight (6.15%) CF patients. Five isolates (17.9%)
were identified as Mycobacterium tuberculosis complex (MTBC), 14 (50%) as Mycobacterium abscessus and nine
(32.1%) as Mycobacterium lentiflavum. All MTBC isolates were found to be susceptible to streptomycin, isoniazid,
rifampicin, and ethambutol. Resistance to some antibiotics was detected in some NTM strains. These are the first
data about the prevalence of mycobacteria in CF patients from Turkey.
Conclusions: In pediatric CF patients, specific mycobacterial analysis of sputum specimens and susceptibility testing
should be performed for allowing early detection, identification and the possibility of eradication of these bacteria.
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Cystic fibrosis (CF) is an autosomal recessive disease
which defects in the Cystic Fibrosis Transmembrane
Conductance Regulator (CFTR) gene product result in
abnormally viscous secretions, mucus plugging of the
airways, intense inflammation, chronic airway infection,
and early death due to progressive bronchiectatic lung
disease [1].
Infection with Mycobacterium tuberculosis complex
(MTBC) strains in this patient group is rarely reported
(1.34-3.41%) [2-8]. These patients are at an increased risk of
pulmonary colonization with opportunistic microorganisms.
Nontuberculous mycobacteria (NTM) are increasingly
isolated from patients with CF, although the clinical
significance of NTM in this population is not yet entirely
understood [1]. It is not known whether these organisms
are transmitted from person to person, acquired from* Correspondence: goncaerkose@yahoo.com
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Person-to-person transmission of NTM has been consid-
ered unlikely. However Aitken et al. [10] recently reported
an outbreak of Mycobacterium abscessus ss massiliense in
five cases with CF. The underlying structural airway disease
and altered mucociliary clearance may be the reasons for
the high prevalence of NTM in this patient group. Potential
risk factors for NTM colonization/infection in CF
include steroid treatment of allergic broncho-pulmonary
aspergillosis and the use of bronchoscopes, aerosolized
medications and tap water contaminated with NTM [9].
Multiple centers all over the world have reported a
prevalence ranging from 1.09% to 22.7% for NTM in
respiratory specimens of CF patients [3,6,7,11-16]. Oliver
et al. [11] prospectively studied 986 CF patients between
10–51 years of age and found a prevalence of 13%. The
author reported that Mycobacterium avium complex
(72%) and Mycobacterium abscessus (16%) were the
most common species. An increased isolation rate of M.
abscessus from CF patients has been reported in severalLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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Society (ATS) published guidelines about the diagnosis
and treatment of lung disease caused by NTM [9]. To
meet criteria for NTM infection, patients must have
compatible clinical findings, compatible radiographic
findings, and bacteriologic findings including three
positive cultures or two positive cultures and a positive
smear for acid-fast bacteria. The first two criteria have
been difficult to apply to patients with CF because of
their longstanding respiratory symptoms, infective
exacerbations, pre-existing radiographic abnormalities
and systemic symptoms [3,9]. The ATS microbiologic
criteria related to this subject, require the following; 1.
Positive culture results from at least two separate sputum
samples or 2. Positive culture result from at least one
bronchial wash or lavage or 3. One or more sputum or
bronchial washings that are culture positive for NTM if
mycobacterial histopathologic features were evident [9].
Because of the risk of increased resistance due to long
term antimicrobial treatment of common CF pathogens,
susceptibility testing is recommended for NTM isolates
from these patients [19]. M. abscessus, which is one of
the most often isolated mycobacteria from CF patients, is
reported to be resistant to most of the antimycobacterials
including tetracyclines, fluoroquinolones, and sulphonamide
[20,21]. Mussaffi et al. [13] reported six CF patients with
NTM pulmonary disease, five of them had positive cultures
for M. abscessus and one had a positive culture for M.
simiae. All six cases were infected with multiresistant
strains. The researchers observed that even when the NTM
was susceptible initially, resistance developed rapidly after
institution of therapy. In another study, M. chelonei and M.
fortuitum were isolated from sputa of two different CF
patients and found to be resistant to all drugs tested [3].
There is only two reports about multidrug resistant
tuberculosis in this patient group. Two M. tuberculosis
strains which were isolated from two patients with
pulmonary infection, found to be resistant to all anti-
biotics [2,8].
The prevalence of mycobacteria in Turkish CF
patients is not known. The aim of the present study
is to reveal the prevalence of MTBC and NTM isolates in
Turkish CF patients and to determine the antimicrobial
susceptibility of isolated species.
Methods
During a 5.5 year study period from April 2003 until
November 2008, sputa which were sent to the Istanbul
Faculty of Medicine, Department of Medical Microbiology
for routine bacteriological or specific mycobacteriological
culture were analyzed. The approval of an ethics committee
was not necessary, because the clinical samples of the study
were taken as part of standard patient care. Informed
consent was given by all patients in this study. During thisperiod a total of 376 respiratory specimens were collected
from 130 patients.
Specimens were processed according to the stand-
ard protocols [22]. All sputa were decontaminated by
N-acetyl-L cysteine (NALC)/ sodium hydroxide (NaOH) and
concentrated by centrifugation (3800 g for 15 min at +4).
Processed specimens were prepared and stained by
the Ziehl-Neelsen (ZN) method. The sediment was
resuspended in 1 ml phosphate buffer (pH 6.8) and
0.4 ml was inoculated into Bactec 12B medium supple-
mented with antibiotics (Becton Dickinson, Spark, MD,
USA) and onto Lowenstein-Jensen medium (Becton
Dickinson, Spark, MD, USA). All cultures were incubated
at 37°C for 10 weeks. The slants were examined twice
weekly for two weeks and then weekly for a further
8 weeks. The Bactec 460 TB vials were controlled every
2 days during the first week and weekly thereafter.
ZN stained smears were prepared from positive Bactec
460 TB vials or LJ cultures. All acid-fast bacilli were
identified to species level by the GenoType Mycobacterium
CM/AS (Hain Lifescience GmbH, Nehren, Germany)
assay.
Antimycobacterial susceptibility testing for MTBC
isolates were performed by the Bactec 460 TB System.
The critical concentrations used for the determination
of resistance to major antimycobacterial agents were
as follows: rifampicin 2 μg/ml, isoniazid 0.1 μg/ml,
ethambutol 2.5 μg/ml, and streptomycin 2 μg/ml [22].
Susceptibility testing for NTM isolates was performed
by the E test method according to the manufacturer’s
instructions to clarithromycin, tigecycline, linezolid,
amikacin, trimethoprim-sulfamethoxazole, doxycycline,
cefoxitin, ciprofloxacin, imipenem, and tobramycin. The
MIC values were evaluated according to the Clinical and
Laboratory Standards Institute. The reference strain
Staphylococcus aureus ATCC 29213 was used for E test,
and H37Rv ATCC 27294 was used for the Bactec 460 TB
System as quality control strains.
Results
A total of 376 sputa from 130 CF patients were investigated
over a period of 5.5 years. The mean age of the patients
was 12.1 ± 3.1 years (range: 5–17). Out of 376 samples, a
total of 28 (7.44%) Mycobacterium spp. were isolated from
eight (6.15%) CF patients. Characteristics, culture and
smear results of Mycobacterium spp. positive patients are
given in Table 1. Five isolates (17.9%) were identified as
MTBC, 14 (50%) as M. abscessus and nine (32.1%) as M.
lentiflavum. The isolation rate according to the patients
was 3.07% (4/130) for MTBC and NTM strains each. Five
MTBC strains were isolated from four different patients
(two times from one patient), 14M. abscessus strains were
isolated from three different patients at different times, and
nine M. lentiflavum strains were isolated from the same




Mycobacterium spp. (n) Co-pathogens
1 M + MTBC (2) Staphylococcus aureus
2 F - MTBC (1) Stenotrophomonas maltophilia, Staphylococcus aureus, Pseudomonas aeruginosa
3 M - MTBC (1) Stenotrophomonas maltophilia, Escherichia coli, Enterobacter spp.
4 F - MTBC (1) Not detected
5 M + M. lentiflavum (9) Stenotrophomonas maltophilia, Staphylococcus aureus, Pseudomonas aeruginosa,
Aspergillus fumigatus
6 F + M. abscessus (10) Stenotrophomonas maltophilia, Pseudomonas aeruginosa, Aspergillus fumigatus
7 F + M. abscessus (3) Pseudomonas aeruginosa
8 F - M. abscessus (1) Pseudomonas aeruginosa
M: Male, F: Female, MTBC: Mycobacterium tuberculosis complex.
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positive and one of four (25%) MTBC positive patients
were also smear positive. The contamination rate of
cultures was 9.8% (37/376). Co-pathogens isolated together
with Mycobacterium spp. were Pseudomonas aeruginosa
(n = 5), S. aureus (n = 4), Stenotrophomonas maltophilia
(n = 4), and Aspergillus fumigatus (n = 2). The characteristics
of all patients, smear results and the distribution of
co-colonizing bacteria are given in Table 2.
All MTBC isolates were found to be susceptible to
streptomycin, isoniazid, rifampicin, and ethambutol.
All M. abscessus isolates were susceptible to clari-
thromycin (MICs 0.125-1 μg/ml) and tigecycline
(MICs 0.19 -0.5 μg/ml). Eleven (78.6%) of 14 strains
were determined as susceptible to linezolid (MICs
4 μg/ml), while the remaining three (21.4%) were re-
sistant (MICs >256 μg/ml). One strain (7.1%) was
found to be resistant to amikacin (MIC > 256 μg/ml)
and 13 strains (92.8%) showed intermediate MICs
(32–48 μg/ml). All M. abscessus isolates were resistant to
trimethoprim-sulfamethoxazole (MICs > 32 μg/ml), doxy-
cycline (MICs >256 μg/ml), cefoxitin (MICs >256 μg/ml),Table 2 The characteristics of patients and the
distribution of co-colonizing bacteria
Characteristic MTBC and
NTM (−)
MTBC (+) NTM (+)
Total (n = 130) 122 4 4
Female (%) 58 (47.5) 2 (50) 3 (75)
Mean age (years) 12.1 ± 3.2 11.5 ± 1.2 15.5 ± 1.7
Pseudomonas aeruginosa (%) 26.51 - 100
Staphylococcus aureus (%) 28.03 50 50
Stenotrophomonas maltophilia (%) 10.10 50 50
Haemophilus influenza (%) 8.83 - -
Aspergillus species (%) 8.08 - 50
Streptococcus pneumoniae (%) 4.54 - -
Klebsiella pneumonia (%) 1.51 - -ciprofloxacin (MICs >32 μg/ml), imipenem (MICs >32
μg/ml) and tobramycin (MICs >256-64 μg/ml).
All of the M. lentiflavum isolates were susceptible to
clarithromycin (MICs 0.25 μg/ml), amikacin (MICs
12 μg/ml) and ciprofloxacin (MICs 0.032 μg/ml), and
resistant to streptomycin (2 μg/ml), isoniazid (0.1 μg/ml),
rifampicin (2 μg/ml), ethambutol (2.5 μg/ml), imipenem
(MICs >32 μg/ml), tigecycline (MICs > 256 μg/ml), cefoxi-
tin (MICs >256 μg/ml), doxycycline (MICs 128 μg/ml),
and tobramycin (MICs 64 μg/ml).
Discussion
There is little information about pulmonary tuberculosis in
CF patients, and only a few cases have been published [2-8].
The isolation rates of MTBC from respiratory samples of
these patients were reported as 1.34-3.41% [3,6,7].
These are the first data about the prevalence of myco-
bacteria in CF patients from Turkey. In our study, MTBC
was isolated from sputa of four out of 130 patients
(3.07%). This rate is similar to the results reported from
other studies.
NTM have emerged as new pathogens in CF patients re-
cently [23]. CF centers worldwide have reported isolation
rates ranging from 1.09% to 22.7% [7,12,13,15,16,19,24-27].
We found that during the study period 3.07% (4/130) of
Turkish CF patients had NTM in their sputum samples.
Three of these patients (75%) had positive smears, and
met the ATS microbiologic criteria [9].
Recovery of NTM from sputa of CF patients is usually
hampered by the presence of other bacteria, especially
P. aeruginosa, which is able to survive after routine
sputum decontamination using NALC-NaOH. The
Centers for Disease Control and Prevention recommend
5% oxalic acid (OxA) as decontaminating agent for CF
specimens [28]. Whittier at al. [29] showed that using 5%
OxA after NALC-NaOH resulted with decrease in con-
tamination rates and increase in recovery of mycobacteria.
However Bange et al. [30] reported that although the
contamination rate was reduced with NALC-NaOH-OxA,
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the same. In addition, Radhakrishnan et al. [19] pointed
out that decontamination with NALC-NaOH-OxA
may be too harsh and eliminate NTM in smear negative
samples with lower numbers of mycobacteria. In an multi-
center investigation Whittier et al. [28] concluded that
although with the NALC-NaOH-OxA method NTM were
successfully recovered from samples with AFB smear
scores of 3+/4+, but this was problematic in low inoculum
samples with AFB smear scores of 1+/2+. In the current
study, only NALC-NaOH was used as decontaminating
agents. Three of four (75%) NTM positive and one of four
(25%) MTBC positive samples were smear positive with
scores of 1+/2+. Using OxA could have resulted with
decrease in recovery rates of mycobacteria.
M. abscessus is a rapid growing mycobacterium (RGM)
which is reported as a causative agent of respiratory
disease in patients both with and without predisposing
conditions, and cutaneous disease usually following
accidental trauma or surgery [9]. It is one of the
NTM that are most commonly isolated from CF patients,
especially at younger ages [9,13,20]. M. abscessus isolates
are uniformly resistant to standard antituberculous agents
and infection with these microorganisms is extremely
difficult to treat. Antibiotic susceptibility testing of clinic-
ally significant isolates is recommended due to variable
in vitro drug susceptibilities to some drugs. Acquired
mutational resistance to clarithromycin and amikacin can
occur [9,31].
The isolation rate of M. abscessus from pulmonary
samples of CF patients was reported as 1.1-14.1%
[11-14,25,26]. Reported rates of pulmonary infection
with these species according to the ATS microbiologic
criteria was 1.5-3.8% [13,15,17,24,27].
In the current study, M. abscessus was the most
commonly isolated NTM species (60.9% of NTM species).
M. abscessus was isolated from three patients with an
isolation rate of 2.3%, and two of these patients (1.5%) met
the ATS microbiologic criteria (positive culture results
from at least two separate sputum samples) [9]. Although
the isolation rate of this species from sputa of Turkish CF
patients is low, it is in concordance with results reported
from other studies.
M. lentiflavum is placed between the most commonly
isolated newly described NTM species from clinical samples
[32]. It was reported as the agent of cervical lymphadenitis
mostly in children, skin and invasive infections, and a
few respiratory tract infections have been detected in both
immunocompetent and immunocompromised patients
[32-34]. Because of its low virulence, the isolation of
this species does not usually refer to an infection
[32]. Immunosupression is a risk factor for infection with
M. lentiflavum [33]. Resistance to primer antituberculous
drugs is commonly reported [32-35].There are a few studies which reported the isolation of
M. lentiflavum from respiratory samples of CF patients
with a rate of 0.06-20% [6,11,15,17]. However, none
of these studies reported a case which meets the ATS
criteria for pulmonary infection.
In this study, M. lentiflavum was isolated from one
patient’s (0.8%) nine separate samples, and this patient
met the ATS microbiologic criteria. M. lentiflavum
was consisted of 39.1% of NTM species isolated in the
current study. The isolation rate of this species is similar
to the rate which was reported in the other studies.
Oliver et al. [11] compared CF patients with and with-
out NTM and found that culture-positive subjects had a
higher frequency of S. aureus and a lower frequency
of P. aeruginosa. They hypothesized that the presence
of S. aureus may create conditions which can favor
the presence of NTM in the airways. However Levy et al.
[24] noted that there was no difference among the isolation
rates of S. aureus from culture positive and negative
patients regarding NTM. Interestingly, Musaffi et al. [13]
and Levy et al. [24] reported that CF patients with NTM
colonization and lung disease had higher frequency of
P. aeruginosa. The same was observed in the current
study. The rate of NTM and S. aureus co-colonization
was 21.7%, whereas the rate of NTM and P. aeruginosa
co-colonization was higher as 34.7%.
Long term use of macrolide in CF patients was shown
to be a risk factor for NTM infection, especially with M.
abscessus [24]. Renna et al. [36] showed that concentra-
tions of azithromycin inhibited intracellular killing of
mycobacteria in macrophage by impairing autophagic and
phagosomal degradation and resulted in chronic infection
in a mouse model. However, as there are some studies
which have not established any association [19,26,37,38],
the link between chronic macrolide use and NTM
infection remains indeterminate.
In this study nine of the patients had long term
macrolide therapy. Two of them (22.2%) had infection
with M. abscessus, one (11.1%) had infection with M.
lentiflavum, and one (11.1%) other patient had infection
with MTBC. As number of patients using macrolide is
very small, the relationship between macrolide use and
NTM infection could not get analyzed statistically.
In CF patients there is often poor correlation between
in vitro drug susceptibility testing and clinical response
for most antimicrobial drugs except for the macrolides.
For Mycobacterium avium complex, susceptibility
testing to macrolides is recommended because of the
correlation with clinical response. Macrolide sensitiv-
ity testing and identification of the exact subspecies
of M. abscessus also provides useful information for
the treatment. Because of a deletion in the inducible
erythromycin ribosome methyltransferase (erm) gene,
M. abscessus subspecies massiliense is susceptible to
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abscessus ss bolletii is resistant [39,40].
There are only three studies which reported the drug
susceptibility of MTBC strains which were isolated from
CF patients. Asherova et al. [2] isolated two MTBC
strains from two CF patients with pulmonary infection
and found out that the two strains were resistant to all
antibiotics tested. Smith et al. [3] isolated MTBC from
sputa of three CF patients and reported that these
three strains were susceptible to streptomycin, isoniazid,
rifampicin, ethambutol, p-aminosalicylic acid, ethionamide,
cycloserine, capreomycin, and kanamycin. Two of these
strains were susceptible to pyrazinamide, while one strain
was resistant. In the case report by Manika et al. [8]
the strain was found resistant to streptomycin, isoniazid,
rifampicin, ethambutol, pyrazinamide and quinolones,
while it was susceptible to amikacin, kanamycin and
capreomycin. In the current study all of MTBC isolates
were found to be susceptible to streptomycin, isoniazid,
rifampicin, and ethambutol.
M. abscessus is one of the NTM species which is most
commonly isolated from CF patients and known to be
the most pathogenic and chemotherapy-resistant
RGM [9,13,20]. However there are only a few reports
about the drug resistance of strains isolated from CF
patients. Sanguinetti et al. [21] isolated M. abscessus
from a CF patient which developed fatal disseminated
infection. This strain was found to be resistant to
streptomycin, isoniazid, rifampicin, ceftazidime, clarithro-
mycin, levofloxacin, vancomycin, imipenem, amoxicillin,
ethionamide, trimethoprim-sulfamethoxazole, ofloxacin,
and amoxicillin-clavulanic acid. In another study, M.
abscessus, which was the causative agent of a pulmonary
infection in a CF patient, was initially susceptible to
clarithromycin, ethambutol, amikacin, mefoxitin and
developed in vitro resistance to all these drugs except
for ethambutol after therapy [41]. Jönsson et al. [15]
recovered a M. abscessus strain from a CF patient
with persistent airway colonization, and detected that it
was resistant to rifabutin, clarithromycin, clofazimine, and
amikacin. In the current study all of the M. abscessus
isolates were susceptible to clarithromycin and tigecycline.
Eleven (78.6%) of 14 strains were determined as suscep-
tible to linezolid, while the remaining three (21.4%) were
resistant. One strain (7.1%) was found to be resistant to
amikacin and 13 strains (92.9%) showed intermediate
sensitivity pattern. All of M. abscessus isolates were
resistant to trimethoprim-sulfamethoxazole, doxycycline,
cefoxitin, ciprofloxacin, imipenem, and tobramycin.
Although the isolation ofM. lentiflavum from respiratory
samples of CF patients is reported in a few studies, there is
no information about the susceptibility pattern of these
strains [6,11,15,17]. In studies with M. lentiflavum strains
isolated from non-CF patients, this species was usuallyfound to be resistant to primary antituberculous drugs
[32-35]. However, strains which are susceptible to
clarithromycin, amikacin, ciprofloxacin, cycloserin,
canamycin, and ofloxacin are reported [32,34,35]. In this
study, all of M. lentiflavum isolates were susceptible to
clarithromycin, amikacin, and ciprofloxacin, while they
were fully resistant to streptomycin, isoniazid, rifampicin,
ethambutol, imipenem, tigecycline, cefoxitin, doxycycline,
and tobramycin.
Conclusions
Even though infection by MTBC in CF patients is rare,
pulmonary infections due to NTM are increasingly being
reported [2-4,7,11,14]. These are the first data about the
prevalence of mycobacteria in CF patients from Turkey.
We recovered MTBC from sputa of these patients
with a rate of 3.07%, and the isolation rate of NTM
in this study is 3.07%. In pediatric CF patients, specific
mycobacterial analysis of sputum specimens are not
routinely performed. In our opinion this should be
done for allowing early detection, identification and
the possibility of eradication of these bacteria. As
these patients are under heavily antibiotic treatment,
infection with resistant strains may occur. Because we
detected resistance to some antibacterials in NTM
strains, we propose that susceptibility testing should
be performed for the NTM strains isolated.
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